Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Clinigen - AIM billionaire the latest member of an elite club

Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
test tubes
The company seems to have the formula for success. Listed with a market capitalisation of £135mln, it is now worth £1.3bn

London’s junior market doesn’t always receive the best press. Founded more than two decades ago, Aim was supposed to be the low-cost incubator for Britain’s fledgeling businesses.

In some quarters it has gained a reputation as an overpriced, under-regulated casino inhabited by thieves and blaggards.

Granted there have been some spectacular blow-ups on Aim, such as Quindell, and there are businesses that run out of cash or ideas. But that is only to be expected given the immaturity of companies on the exchange.

But never ever have we seen on Aim anything of the scale of Carillion, which as well as wiping billions off the value of people’s savings, could drag with it down the plughole tens of thousands of jobs.

And of course, before that, there was the banking crisis, which posed a systemic threat.

Risky, racy but bringing through the next generation  

So, while Aim’s risky, racy reputation is well deserved, nothing will damage your wealth more than a snafu at one of the market’s so-called blue-chips.

We shouldn’t forget there have been some huge success stories among the so-called ‘junior’ ranks. The clothing retailer ASOS leads the pack with a market capitalisation of £5.6bn. This would qualify it for a berth in the FTSE 100 if management was prepared to fill in the paperwork required.

Next in the AIM list comes Hutchison China Meditech (£3.7bn), followed by the drinks group Fevertree (£2.6bn).

In all, there are 16 companies valued at over £1bn, which shows the alternative market is fulfilling its primary role – creating the market’s next generation of winners (albeit from a dubious gene pool).

The latest company to swell the ranks of the ‘£1bn club’ is Clinigen, a speciality pharma and pharma services group that joined Aim back in September 2012.

Its shares were listed for 164p each and are now changing hands for £10.70, valuing it at £1.3bn.

Your investment would have grown exponentially 

Had you bought £1,000 worth of stock at the IPO, it would be worth in excess of £6,500 today (excluding dividend payments).

Back in late 2012 Clinigen provided clinical trial supply services and sold a number of niche products, the most valuable of which was an oncology drug called Foscavir.

In its first full year as a listed company its revenues were £123mln, giving underlying profits of £20mln.

WATCH: Clinigen chief in upbeat mood

READ: Company primed for another year of growth

Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions.

This year sales are expected to be around £370mln, rising to £405mln, giving adjusted profits of £77mln and £93mln respectively.

Clinigen’s most recent purchase, the £150mln takeover of Quantum Pharma, shows the company has become more ambitious in its deal-making.

The last update revealed the contribution from Quantum is yet to make its full impact on the profit and loss account, while there will undoubtedly be significant cost-savings and synergies from a union of this kind.

Deals no longer bite-sized

The risk, however, as the deal flow expands from the bite-sized to the five-course variety, is these transactions are harder to digest. In other words, there is more scope to muck them up.

The early feedback from Clinigen is that Quantum is bedding in well, and, crucially, cash flow used to service the firm’s £142mln of debt has been good.

Looking at Clinigen’s investment credentials, based on peers in the pharma and pharma services business the stock would appear to be a little pricey on just under 22-times this year’s earnings; however, the multiple falls to 18 times next year and just 16 by 2020, which unwinds the shares’ premium rating.

It should also be pointed out Clinigen pays a dividend, though at an estimated 5.3p the yield isn’t the most generous.  

Charles Weston, healthcare analyst at the London arm of the German bank Berenberg, is a fan. He rates the stock a ‘buy’, values it at £12 a share, and likes its “growth profile [and] diversified revenue stream”.

Given its size, the pace at which it is growing and undoubted demand for stock from institutions that can’t invest in the junior market, one wonders how long it will be before the company moves its listing to the FTSE 250.

View full CLIN profile View Profile

Clinigen Group PLC Timeline

Related Articles

researcher filling a vial
May 29 2018
ImmuPharma chairman Tim McCarthy said: "We continue to believe Lupuzor has the potential to bring a much needed treatment to Lupus sufferers around the world"
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
mri scanner
June 06 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use